The moderate GH release is sufficient for most research endpoints, and the clean hormonal profile avoids confounding variables in study design
However, based on the information available to us, we continue to believe that C1763 and C1765 may describe the Axoguard HA+ Nerve Protector TM
Track my water, fiber and calories
Retatrutide, Amycretin, Survodutide, VK2735, and MariTide are among the most watched pipeline assets heading into 2026 because each represents a different answer to the same commercial question: what comes after Ozempic, Wegovy, Mounjaro, and Zepbound
however, we maintain some of our concerns listed in the CY 2026 OPPS/ASC proposed rule (90 FR 33588 through 35589), including the lack of comparative data between the Axoguard HA+ Nerve Protector TM and the predicate device and other currently available treatments for the indicated condition